Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid  Injectable Fillers

Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid Injectable Fillers

  • First-of-its-kind report is available at www.naturallyyouwithHA.com
  • Deep dive into category education and data on HA injectable fillers and the natural-looking results they can achieve

- Allergan Aesthetics, an AbbVie company, has launched the " Naturally You with Injectable Hyaluronic Acid Fillers" campaign aimed to providing clear, factual education about HA injectable fillers. This initiative focuses on correcting misinformation to elevate understanding and celebrate the safe, natural-looking outcomes possible with hyaluronic acid injectable fillers.

"Our goal with Naturally You with Injectable Hyaluronic Acid Fillers campaign is to set the record straight on hyaluronic acid injectable fillers for our healthcare providers, our patients and the category," said Glen Curran , Senior Vice President, U.S. Aesthetics, Allergan Aesthetics. "By providing facts, real-world satisfaction data and expert insights, we hope to truly show how HA fillers are a safe and effective way to address aesthetic concerns."

The new report, The Hyaluronic Acid Injectable Fillers Report, is at the center of the campaign and sheds light on the current use, opinions and personal experiences around of HA injectable fillers.

Key stats include:

  • Nearly 90% of consumers indicate they are satisfied with the outcome, noting natural-looking results as their top satisfaction point. 1
  • 78% of consumers strongly agree that today, people want a more natural look.
  • Over two-thirds of consumers use social media and online videos to learn about HA fillers.
  • Over 75% of consumers believe that more people will use injectable HA fillers in the future. 2

The report draws from extensive research, including analysis of consumer and business media, cultural conversations, social trends, and proprietary U.S. data from Allergan Aesthetics, the market-leader in HA injectable fillers. Insights were further validated through interviews with four leading aesthetics experts from key U.S. markets: Brittony Croasdell , NP, Chicago, IL ; Lisa Espinoza , MD, PA; Emily Hu , MD, Portland, OR ; and Terrence Keaney , MD, Washington, DC —and a foreword by award-winning beauty journalist, Jamie Rosen , reflecting on how far the aesthetics category has come and what's ahead.

The Hyaluronic Acid Injectable Fillers Report is the first in the Aesthetics Evolution Report Series, which will continue to provide insights into the aesthetics industry.

As part of the Naturally You with Injectable Hyaluronic Acid Fille rs campaign, Allergan Aesthetics will partner with healthcare providers and consumer influencers, to support education on the category and promotion of healthy, natural-looking outcomes consumer desire today.

Join Allergan Aesthetics in reshaping the narrative around HA injectable fillers. Explore the report and be part of a more informed future in aesthetics.

Visit www.naturallyyouwithHA.com to learn more and download your copy of The Hyaluronic Acid Injectable Fillers Report .

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com .

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @AbbVie on LinkedIn, Facebook , Instagram , X (formerly Twitter) , and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

U.S. Media:
Kate McShane
Corporate Communications
Kate.mcshane@allergan.com

References:

  1. Allergan Aesthetics U.S. HA Filler Category Data and Innovation Scan
  2. Allergan Aesthetics 2025 Global HA Filler Future Study

Data in the report is collected on a continuous basis via multiple ongoing surveys, with variable sample sizes per measure (total HCP n = ~100; consumer n = ~241 – 1,180).

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/allergan-aesthetics-launches-campaign-to-educate-consumers-about-hyaluronic-acid-ha-injectable-fillers-302544294.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1
- RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3

AbbVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6 to 17 years

- Twenty-nine abstracts showcase AbbVie's vast portfolio and continued commitment to changing the way patients living with gastrointestinal disorders manage their condition

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds.

"We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing. We would like to thank Dr. Linda Pullan of Pullan Consulting who assisted with our current success."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With global spending on medicine using list prices growing by 38 percent over the past five years and a forecasted increase of 35 percent through 2029, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded the scope of the contract to include all of Maccabi's pharmacies and additional nurses. Maccabi is the second largest Healthcare Management Organization ("HMO") in Israel, serving over 2.6 million Israelis and is renowned for its use of technology and emphasis on patient-centered care, according to Maccabi's website here.

Pursuant to the amended agreement, Seegnal will continue to deliver its patented prescription co-pilot platform for an additional six years, to September 22, 2031, while expanding the scope to nurses and pharmacists in all of Maccabi's nationwide pharmacies. Maccabi is the first in Israel and one of the first HMOs worldwide to offer an end-to-end safety coverage throughout the patient journey, allowing complete visibility to pharmacists in the pharmacies into clinician decision while prescribing patient centric medication. The expanded contract was changed from a fixed base contract to Seegnal's current SaaS based model based on Quarterly Recurring License Fees and is expected to generate additional revenue for the Corporation.

Keep reading...Show less
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc.  (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News